X4 Pharmaceuticals
Cambridge
About X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment. The company is developing two unique programs such as drug candidate, X4P-001, has clinical experience in over 70 subjects, and is advancing into Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC) and refractory epithelial ovarian cancer (EOC), the second program, X4P-002, is a unique series of late lead molecules that penetrate the blood-brain barrier. They will pursue early clinical development in glioblastoma multiforme (GBM), a rare form of lethal brain cancer, for the X4P-002 program.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 101 – 250
- Estimated revenue: $1K – $10K
- Total funding: $760.6M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:XFOR
- Website: x4pharma.com
- Phone: +1 857 529 8300
Industries & Categories
Biotechnology, Clinical Trials, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/x4-pharmaceuticals-145864 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.